Ischemic stroke is a leading cause of death and disability worldwide. Much of the long-term disability occurs in patients with emergent large vessel occlusion (ELVO).
In fact, in these patients, occlusion of a major intracerebral artery results in a large area of brain injury often resulting in death or severe disability. Until recently, intravenous tissue plasminogen activator (t-PA) was the only proven treatment for ELVO.